Literature DB >> 23024029

2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.

Dinesh Khanna1, Puja P Khanna, John D Fitzgerald, Manjit K Singh, Sangmee Bae, Tuhina Neogi, Michael H Pillinger, Joan Merill, Susan Lee, Shraddha Prakash, Marian Kaldas, Maneesh Gogia, Fernando Perez-Ruiz, Will Taylor, Frédéric Lioté, Hyon Choi, Jasvinder A Singh, Nicola Dalbeth, Sanford Kaplan, Vandana Niyyar, Danielle Jones, Steven A Yarows, Blake Roessler, Gail Kerr, Charles King, Gerald Levy, Daniel E Furst, N Lawrence Edwards, Brian Mandell, H Ralph Schumacher, Mark Robbins, Neil Wenger, Robert Terkeltaub.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23024029      PMCID： PMC3662546          DOI： 10.1002/acr.21773

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN： 2151-464X            Impact factor:   4.794


× No keyword cloud information.
  62 in total

1.  Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study.

Authors:  Alexander So; Marc De Meulemeester; Andrey Pikhlak; A Eftal Yücel; Dominik Richard; Valda Murphy; Udayasankar Arulmani; Peter Sallstig; Naomi Schlesinger
Journal:  Arthritis Rheum       Date:  2010-10

2.  Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy.

Authors:  Michael A Becker; Patricia A MacDonald; Barbara J Hunt; Christopher Lademacher; Nancy Joseph-Ridge
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2008-06       Impact factor: 1.381

3.  A survey of current evaluation and treatment of gout.

Authors:  Naomi Schlesinger; Dirk F Moore; Jennifer D Sun; H Ralph Schumacher
Journal:  J Rheumatol       Date:  2006-10       Impact factor: 4.666

Review 4.  Chronic gout: epidemiology, disease progression, treatment and disease burden.

Authors:  Richard A Brook; Anna Forsythe; James E Smeeding; N Lawrence Edwards
Journal:  Curr Med Res Opin       Date:  2010-11-04       Impact factor: 2.580

5.  The economic burden of gout on an employed population.

Authors:  Richard A Brook; Nathan L Kleinman; Pankaj A Patel; Arthur K Melkonian; Truman J Brizee; James E Smeeding; Nancy Joseph-Ridge
Journal:  Curr Med Res Opin       Date:  2006-07       Impact factor: 2.580

Review 6.  [New therapeutic options for gout].

Authors:  Pascal Richette; Sébastien Ottaviani; Thomas Bardin
Journal:  Presse Med       Date:  2011-06-17       Impact factor: 1.228

7.  Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis.

Authors:  Gregory C Borstad; Leslie R Bryant; Michael P Abel; Daren A Scroggie; Mark D Harris; Jeff A Alloway
Journal:  J Rheumatol       Date:  2004-12       Impact factor: 4.666

8.  Comparison of drug adherence rates among patients with seven different medical conditions.

Authors:  Becky A Briesacher; Susan E Andrade; Hassan Fouayzi; K Arnold Chan
Journal:  Pharmacotherapy       Date:  2008-04       Impact factor: 4.705

Review 9.  Measuring quality in arthritis care: the Arthritis Foundation's quality indicator set for analgesics.

Authors:  Kenneth G Saag; Jason J Olivieri; Fausto Patino; Ted R Mikuls; Jeroan J Allison; Catherine H MacLean
Journal:  Arthritis Rheum       Date:  2004-06-15

10.  Determining mild, moderate, and severe pain equivalency across pain-intensity tools in nursing home residents.

Authors:  Katherine R Jones; Carol P Vojir; Evelyn Hutt; Regina Fink
Journal:  J Rehabil Res Dev       Date:  2007
View more
  178 in total

1.  Medically managed gout precipitating acute carpal tunnel syndrome.

Authors:  Logan Carr; Sebastian Brooke; John Ingraham
Journal:  Hand (N Y)       Date:  2015-09

2.  A case of acute kidney injury secondary to black cherry concentrate in a patient with chronic kidney disease secondary to type 2 diabetes mellitus.

Authors:  Mohamad Matout; Alex S Halme; Jeffrey Wiseman
Journal:  CEN Case Rep       Date:  2019-04-08

3.  3,4-Dihydroxy-5-nitrobenzaldehyde (DHNB) is a potent inhibitor of xanthine oxidase: a potential therapeutic agent for treatment of hyperuricemia and gout.

Authors:  Jian-Ming Lü; Qizhi Yao; Changyi Chen
Journal:  Biochem Pharmacol       Date:  2013-08-30       Impact factor: 5.858

4.  As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.

Authors:  A-K Tausche; M Christoph; M Forkmann; U Richter; S Kopprasch; C Bielitz; M Aringer; C Wunderlich
Journal:  Rheumatol Int       Date:  2013-09-12       Impact factor: 2.631

5.  Managing Gout Flares in the Elderly: Practical Considerations.

Authors:  Abhishek Abhishek
Journal:  Drugs Aging       Date:  2017-12       Impact factor: 3.923

6.  The degree of asymptomatic hyperuricemia and the risk of gout. A retrospective analysis of a large cohort.

Authors:  Hadar Duskin-Bitan; Eytan Cohen; Elad Goldberg; Tzippy Shochat; Amos Levi; Moshe Garty; Ilan Krause
Journal:  Clin Rheumatol       Date:  2014-02-13       Impact factor: 2.980

Review 7.  Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat.

Authors:  Bishoy Kamel; Garry G Graham; Kenneth M Williams; Kevin D Pile; Richard O Day
Journal:  Clin Pharmacokinet       Date:  2017-05       Impact factor: 6.447

Review 8.  The gouty tophus: a review.

Authors:  Ashika Chhana; Nicola Dalbeth
Journal:  Curr Rheumatol Rep       Date:  2015-03       Impact factor: 4.592

Review 9.  Treatment Options for Gout.

Authors:  Bettina Engel; Johannes Just; Markus Bleckwenn; Klaus Weckbecker
Journal:  Dtsch Arztebl Int       Date:  2017-03-31       Impact factor: 5.594

10.  New ACR guidelines for gout management hold some surprises.

Authors:  Thomas Bardin; Pascal Richette
Journal:  Nat Rev Rheumatol       Date:  2012-12-11       Impact factor: 20.543
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.